Abstract
Methylphenidate (MPH) is a centrally acting (psycho)stimulant which reversibly blocks the dopamine re-uptake transporter. At present MPH is one of the most frequently prescribed drugs for the symptomatic treatment of attention deficit hyperactivity disorder (ADHD). Although MPH has been in use for about 50 years, there is no information available concerning the long-term benefits and risks of medication. Based on experiments in rats it has been suggested that MPH treatment may affect the maturation of central dopaminergic systems and may be a risk factor for the development of Parkinson’s disease (PD). The aim of the present case-control study was to gain information about (1) ADHD-like symptoms that may precede PD motor symptoms, and (2) the exposure to psychostimulants in childhood. We used a German short version of the Wender Utah Rating Scale (WURS-k, Retz-Junginger et al., 2002) which is a reliable measure for the retrospective diagnosis of childhood ADHD, and another questionnaire including a rating scale for symptoms of ADHD in childhood (Q-ADHD-Child) according to DSM-IV and ICD-10 criteria.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53: 1026–1031
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Scitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415–445
Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366: 237–248
De Rijk MC, Tzourio C, Breteler MMB, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe. The EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 63: 10–15
Fox MJ (2002) A memoir. Hypericon, New York
Gerlach M (2003) ADS/ADHS. Stimulanzien-Therapie: Gefahr für Kinder und lugendliche? pädiatrie hautnah 2: 83–87
Gerlach M, Banaschewski T, Warnke A, Rothenberger A (2003) Parkinson’s disease following methylphenidate administration in childhood? An empirical assessment of the current situation. Nervenheilkunde 22: 80–84
Ishihara L, Brayne CA (2006) Review article. A systematic review of depression and mental illness preceding Parrkinson’s disease. Acta Neurol Scand 113: 211–220
Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Calne DB (ed) Handbook of experimental pharmacology, vol. 88. Springer, Berlin Heidelberg New York, pp 47–112
Lees AJ (1992) When did Ray Kennedy’s Parkinson’s disease begin? Mov Disord 7: 110–116
Lieberman A (2006) Review article. Depression in Parkinson’s disease-a review. Acta Neurol Scand 113: 1–8
Moll GH, Hause S, Ruther E, Rothenberger A, Hüther G (2001) Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 11: 15–24
Müller T (2004) Mood disorders in early Parkinson’s disease. Curr Opin Psychiatry 17: 191–196
Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson’s disease. Neurology 65: 1239–1245
Rappley MD (2005) Attention deficit-hyperactivity disorder. N Engl J Med 352: 165–173
Remschmidt H, Schmidt MH, Poustka F (2006) Multiaxiales Klassifikationsschema für psychische Störungen des Kindes-und lugendalters nach ICD-10 der WHO. Huber, Bern
Retz-lunginger P, Retz W, Blocher D, Weijers HG, Trott GE, Wender PH, Rösler M (2002) Wender Utah Rating Scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 73: 830–838
Retz-lunginger P, Retz W, Blocher D, Stieglitz RD, Georg T, Supprian T, Wender PH, Rösler M (2003) Reliability and validity of the German short version of the Wender-Utah Rating Scale for the retrospective assessment of attention deficit/hyperactivity disorder. Nervenarzt 74: 987–993
Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277–301
Roeltgen DP, Schneider JS (1991) Chronic low-dose MPTP in nonhuman primates: A possible model for attention deficit disorder. J Child Neurol Suppl 6: S80–S87
Sian J, Gerlach M, Youdim MBH, Riederer P (1999) Parkinson’s disease: a major hypokinetic basal ganglia disorder. J Neural Transm 106:443–476
Walitza S, Herhaus G, Melfsen, Scheuerpflug P, Warnke A, Gerlach M (2005) Hyperactivity precedes the parkinsonian symptoms in patients with early-onset Parkinson’s disease. 16th International Congress on Parkinson’s Disease and Related Disorders, 5–9th June, Berlin. Parkinson Rel Disord Suppl 2, 11: Pt005–Pt010, 125
Ward MF, Wender PH, Reimherr FW (1993) The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry: 150: 885–890
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag
About this paper
Cite this paper
Walitza, S. et al. (2007). Association of Parkinson’s disease with symptoms of attention deficit hyperactivity disorder in childhood. In: Gerlach, M., Deckert, J., Double, K., Koutsilieri, E. (eds) Neuropsychiatric Disorders An Integrative Approach. Journal of Neural Transmission. Supplementa, vol 72. Springer, Vienna. https://doi.org/10.1007/978-3-211-73574-9_38
Download citation
DOI: https://doi.org/10.1007/978-3-211-73574-9_38
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-73573-2
Online ISBN: 978-3-211-73574-9
eBook Packages: MedicineMedicine (R0)